Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_165_18
Metastatic Merkel Cell Carcinoma of the Abdominal Wall
Financial support and sponsorship Nil.
Abstract
Merkel-cell carcinoma (MCC) is a rare skin malignancy seen in elderly males. It is a highly aggressive tumor with a poor prognosis. Surgery is the mainstay of treatment for localized disease with adjuvant radiation depending on the locoregional extent, while chemotherapy has a role in metastatic disease. Emerging data from treatment with immune checkpoint inhibitors look promising. We report a case of MCC in an elderly male diagnosed and treated with chemotherapy and radiation, with a review of the literature of this rare malignancy.
Publication History
Received: 24 July 2018
Accepted: 14 October 2019
Article published online:
23 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Schrama D, Ugurel S, Becker JC. Merkel cell carcinoma: Recent insights and new treatment options. Curr Opin Oncol 2012; 24: 141-9
- 2 Miller RW, Rabkin CS. Merkel cell carcinoma and melanoma: Etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 1999; 8: 153-8
- 3 Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF. et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: The AEIOU features. J Am Acad Dermatol 2008; 58: 375-81
- 4 Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972; 105: 107-10
- 5 De Wolff-Peeters C, Marien K, Mebis J, Desmet V. A cutaneous APUDoma or Merkel cell tumor? A morphologically recognizable tumor with a biological and histological malignant aspect in contrast with its clinical behavior. Cancer 1980; 46: 1810-6
- 6 Lyhne D, Lock-Andersen J, Dahlstrøm K, Drzewiecki KT, Balslev E, Muhic A. et al. Rising incidence of Merkel cell carcinoma. J Plast Surg Hand Surg 2011; 45: 274-80
- 7 Cirillo F, Vismarra M, Cafaro I, Martinotti M. Merkel cell carcinoma: A retrospective study on 48 cases and review of literature. J Oncol 2012; 2012: 749030
- 8 Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 2008; 319: 1096-100
- 9 DeCaprio JA. Merkel cell polyomavirus and Merkel cell carcinoma. Philos Trans R Soc Lond B Biol Sci 2017; 372: pii-20160276
- 10 Wong HH, Wang J. Merkel cell carcinoma. Arch Pathol Lab Med 2010; 134: 1711-6
- 11 Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK. et al. The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93-9
- 12 Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch Surg 1991; 126: 1514-9
- 13 Kritikos N, Priftakis D, Stavrinides S, Kleanthous S, Sarafianou E. Nuclear medicine techniques in merkel cell carcinoma: A case report and review of the literature. Oncol Lett 2015; 10: 1610-6
- 14 Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW. et al. Radiation therapy is associated with improved outcomes in Merkel cell carcinoma. Ann Surg Oncol 2016; 23: 3572-8
- 15 Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck Merkel cell carcinoma: An analysis of 4815 patients. JAMA Otolaryngol Head Neck Surg 2015; 141: 137-41
- 16 Poulsen M, Rischin D, Walpole E, Harvey J, Mackintosh J, Ainslie J. et al. High-risk merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: A Trans-Tasman Radiation Oncology group study – TROG 96:07. J Clin Oncol 2003; 21: 4371-6
- 17 Ito Y, Kawamura K, Miura T, Ueda K, Onodera H, Takahashi H. et al. Merkel cell carcinoma. A successful treatment with tumor necrosis factor. Arch Dermatol 1989; 125: 1093-5
- 18 Su LD, Fullen DR, Lowe L, Uherova P, Schnitzer B, Valdez R. et al. CD117 (KIT receptor) expression in merkel cell carcinoma. Am J Dermatopathol 2002; 24: 289-93
- 19 di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L. et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group. Cancer 1996; 77: 402-8
- 20 National Comprehensive Cancer Network. Clinical Practice Guideline Sinoncology. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [Last accessed on 2019 July 25]
- 21 NCCN Clinical Practice Guidelines in Oncology. Merkel Cell Carcinoma. Ver. 1. 2019th ed. Fort Washington, PA: National Comprehensive Cancer Network, Inc.; 2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. [Last accessed on 2019 Oct 29].
- 22 Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374: 2542-52
- 23 Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D’Angelo SP. et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 2018; 6: 7